68Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series

• DOI: 10.1007/s00259-020-04783-1
• Publication Date: 2020-04-03T09:45:06Z
• Authors: Judith olde Heuvel; Berlinda J. de Wi...; Henk G. van der Poel; Elise M. Bekers; Maarten R. Groote...; Kunal N. Vyas; Cornelis H. Slump; Marcel P. M. Stokkel
• Keywords: Histopathology; Surgical margin

Abstract Purpose Currently, approximately 11–38% of prostate cancer (PCa) patients undergoing radical prostatectomy have a positive surgical margin (PSM) on histopathology. Cerenkov luminescence imaging (CLI) using 68 Ga-prostate-specific membrane antigen ( Ga-PSMA) is novel technique for intraoperative assessment. The aim this first-in-man study was to investigate the feasibility Ga-PSMA CLI . In study, defined as ability distinguish between and negative margin, within 45 min low radiation exposure staff. Methods Six were included in ongoing study. Following perioperative i.v. injection ~ 100 MBq Ga-PSMA, excised immediately imaged ex vivo. Different acquisition protocols tested, hotspots images from intact marked comparison with Results By an protocol 150 s time, 8 × binning 550 nm shortpass filter, PSMs margins (NSMs) visually correctly identified 3 5 patients. Two had hotspot < 0.1 mm excision margin. Conclusion Overall, showed that feasible low-risk assessment PCa. remaining will be used assess diagnostic accuracy technique. Trial registration: NL8256 registered at www.trialregister.nl 04/11/20109.